Santhera Explores Strategic Options; Updates Financial Calendar
Liestal, Switzerland, February 28, 2013 - Santhera
Pharmaceuticals (SIX: SANN) announced today that following the
voluntary withdrawal of Catena® from the Canadian market and
the earlier negative decision of the Committee for Medicinal
Products for Human Use (CHMP) on the Market Authorization
Application for Raxone® in Leber's Hereditary Optic Neuropathy
(LHON), the Board has decided to consider strategic options
including product licensing for Raxone® in LHON and the
possibility of a merger or acquisition. Santhera has already
received expressions of interest from third parties and has
retained Piper Jaffray Limited to assist the Company in this
process.
The publication of the financial results for 2012 will be postponed
and, together with the financial outlook for 2013, will now be
provided within the timelines required by the SIX regulations.
Accordingly, the Company will therefore postpone the Annual
Shareholders' Meeting previously planned for April 22, 2013.
Shareholders should note that whilst the Board believes that it is
in the best interest of shareholders to explore these options and
take the steps described, there can be no guarantee that any
transaction can be consummated.
* * *
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty
pharmaceutical company focused on the development and
commercialization of innovative pharmaceutical products for the
treatment of orphan neuromuscular and mitochondrial diseases, areas
of high unmet medical need with no current therapies. For further
information, please visit www.santhera.com.
For further information, contact
Thomas Meier, Chief Executive Officer
Phone: +41 61 906 89 64
thomas.meier@santhera.com
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to
subscribe for or purchase any securities of Santhera
Pharmaceuticals Holding AG. This publication may contain certain
forward-looking statements concerning the Company and its business.
Such statements involve certain risks, uncertainties and other
factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially
different from those expressed or implied by such statements.
Readers should therefore not place undue reliance on these
statements, particularly not in connection with any contract or
investment decision. The Company disclaims any obligation to update
these forward-looking statements.
Posted: February 2013
